Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › amphetamine

amphetamine

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of amphetamine

7 trials tracked of amphetamine: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 3 citations.

7Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 1 Phase 1 1 Other / NA 3
  1. Phase 3 Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate Completed · 3 cited
  2. Phase 4 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed
  3. Phase 2 Caffeine and Cocaine Completed
  4. Phase 1 A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS) Completed
  5. N/A Neurobiological Principles Applied to the Rehabilitation of Stroke Patients Completed
  6. N/A Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers Completed
Show 1 more trials
  1. N/A Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Mydayis (mixed salts of a single-entity amphetamine) for ADHD in Patients 13 and Older
Psychiatry FDA Approval
FDA Approves Mydayis (mixed salts of a single-entity amphetamine) for ADHD in Patients 13 and Older FDA approves new ADHD drug Mydayis for patients 13 and older
FDA approved Mydayis, a CNS stimulant, for ADHD in patients 13 years and older.
The FDA approved Mydayis, a once-daily stimulant for ADHD in people 13 and older. It can last up to 16 hours, which may cause insomnia. This…
FDA Apr 29, 2026